Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 9/20 | 0.63 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469246 | 1.00 | PRMT1 (0.63) | PRMT1TPSAB1PRSS1F2F10 | |
| SCHEMBL12412058 | 0.91 | PRMT1 (0.66) | PRMT1F2F10F7 | |
| SCHEMBL20184761 | 0.85 | F10 (0.63) | TPSAB1PRSS1F2F10PLG | |
| SCHEMBL17084488 | 0.82 | PRMT1 (0.88) | PRMT1TPSAB1PRSS1F2F10 | |
| SCHEMBL7979972 | 0.82 | PRMT1 (0.88) | PRMT1TPSAB1PRSS1F2F10 | |
| SCHEMBL8815310 | 0.82 | PRMT1 (0.88) | PRMT1TPSAB1PRSS1F2F10 | |
| SCHEMBL8229704 | 0.77 | PRMT1 (1.00) | PRMT1F2F10 | |
| SCHEMBL12412056 | 0.77 | PRMT1 (1.00) | PRMT1TPSAB1F2F10TPSD1 | |
| SCHEMBL8229718 | 0.77 | PRMT1 (0.89) | PRMT1TPSAB1PRSS1F2F10 | |
| SCHEMBL20184755 | 0.76 | PRMT1 (1.00) | PRMT1F2F10PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207801-B1 | METHODS OF INHIBITING VIRAL INFECTION | FUNCTIONAL GENETICS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2207801-B1 | METHODS OF INHIBITING VIRAL INFECTION | FUNCTIONAL GENETICS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8207209-B2 | Methods of inhibiting viral infection | FUNCTIONAL GENETICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2207801-A1 | METHODS OF INHIBITING VIRAL INFECTION | Functional Genetics, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20090170890-A1 | METHOHDS OF INHIBITING VIRAL INFECTION | FUNCTIONAL GENETICS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2009055524-A1 | METHODS OF INHIBITING VIRAL INFECTION | FUNCTIONAL GENETICS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170890-A1 | METHOHDS OF INHIBITING VIRAL INFECTION | CASP8, CASP1, CASP3 | PRMT1 532/4885TPSAB1 1838/4885PRSS1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.